GlassScriptPhysician profile
Geraldo Tosado Jimenez
NPI 1932927340
$2,437.52
in general payments reported to CMS, 2019-2025
36 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $576 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.53 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $309.31 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Eisai INC. | $227.79 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $173.17 | 2024-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $164.65 | 2024-2025 | Ojjaara, Blenrep |
| Merck Sharp & Dohme LLC | $159.64 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $151.55 | 2025 | |
| Myriad Genetic Laboratories, INC. | $149.22 | 2025 | Myrisk |
| Seagen INC. | $92.99 | 2025 | |
| Sobi, INC | $80.14 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $78.44 | 2025 | Tagrisso, Enhertu |
| Pharmaessentia USA Corporation | $75.63 | 2024-2025 | Besremi |
| Genzyme Corporation | $65.66 | 2025 | |
| Daiichi Sankyo INC. | $65.56 | 2025 | Enhertu, Datroway |
| Exelixis INC. | $61.75 | 2024-2025 | Cabometyx |
| Incyte Corporation | $59.58 | 2024-2025 | Jakafi, Monjuvi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $57.16 | 2024-2025 | Ninlaro, Fruzaqla |
| Puma Biotechnology, INC. | $50.58 | 2024 | |
| Agios Pharmaceuticals, INC. | $35.21 | 2025 | Pyrukynd |
| Abbvie INC. | $31.79 | 2025 | |
| Pfizer INC. | $27.10 | 2025 | |
| Stemline Therapeutics INC. | $26.45 | 2025 | Orserdu |
| Tersera Therapeutics LLC | $26.03 | 2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $24.89 | 2024 | |
| Taiho Oncology, INC. | $24.87 | 2024 | |
| Springworks Therapeutics, INC. | $23.27 | 2025 | Ogsiveo |
| Celgene Corporation | $22.62 | 2025 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $22.02 | 2025 | Lynozyfic |
| Ipsen Biopharmaceuticals, INC | $20.50 | 2025 | Tazverik |
| Servier Pharmaceuticals LLC | $19.97 | 2025 | |
| Beone Medicines USA, INC. | $19.46 | 2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $19.05 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.92 | 2025 | Danziten |
| Rigel Pharmaceuticals, INC. | $17.36 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Recordati_rare_diseases_inc. | $14.53 | 2025 | Enjaymo |
| Iovance Biotherapeutics, INC. | $11.68 | 2025 | Amtagvi |
| Pharmaand Gmbh | $8.98 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geraldo Tosado Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.